Codagenix Inc. announced that the U.S. Department of Defense (DoD), through the U.S. Army Medical Research and Development Command and the U.S. Army Medical Research Acquisition Activity, has awarded the company $5.88 million to advance the development of its Codavax-Denv, a tetravalent live attenuated dengue vaccine program.
Opna Bio AG recently provided findings from preclinical studies of novel dual E1A binding protein P300 (EP300) and CREB binding protein (CBP) inhibitors under investigation as potential anticancer agents.
Appili Therapeutics Inc. has secured a commitment for the second stage of funding for ATI-1701 from the U.S. Air Force Academy (USAFA), who is working in partnership with the Defense Threat Reduction Agency, the funding agency.
Researchers from Guangdong University of Technology have reported the discovery of novel fibroblast growth factor receptor 1 (FGFR1) inhibitors as potential candidates for the treatment of glioblastoma multiforme (GBM).
Ankyra Therapeutics Inc. has received approval of its IND application by the FDA and its clinical trial application (CTA) by Health Canada for its lead agent, ANK-101, a novel tumor-directed anchored immune medicine.
Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is a key regulator of immune signaling that supports proliferation and promotes metastasis while maintaining the tumor microenvironment under immunosuppression. Researchers from Exscientia plc and Evotec SE reported on the characterization of EXS-73565.
Mediar Therapeutics Inc. has announced the nomination of two first-in-class monoclonal antibody clinical candidates for fibrosis. The first, MTX-463, is designed to neutralize WISP-1 signaling. The second candidate, MTX-474, is designed to neutralize EphrinB2 signaling.
Glutaminyl-peptide cyclotransferase-like protein (QPCTL) is a modulator of CD47-SIRPα binding and can be targeted to achieve antitumor responses through myeloid checkpoint blockade. At the recent ESMO meeting in Madrid, researchers from Insilico Medicine Inc. reported the preclinical characterization of ISM-8207, a QPCTL inhibitor with activity against triple-negative breast cancer (TNBC) and diffuse large B-cell lymphoma (DLBCL).
To understand the human brain, an international consortium of scientists has created the most complete atlas of this organ to date. The map reveals the anatomy, the architecture of the tissues, how or where each cell is, their function, gene expression and regulation. On Oct. 12, 2023, Science and Science Advances published a group of 21 studies that unveiled the map of the human brain, as well as the brains of nonhuman primates and mice, cell by cell, for an adult model and for the different stages of development.